Paxlovid significantly shortened the time to symptom relief (median, 13 vs 15 days; hazard ratio [HR], 1.27) and resolution ...

Merck & Co. Inc.'s stock swung between gains and losses premarket Thursday, after the drug company beat profit and sales estimates for the third quarter, but lowered guidance due to deals with ...

The drug is also approved in Singapore. Xocova belongs to the same class of drugs as Pfizer’s (PFE) Paxlovid and Merck’s (MRK) Lagevrio, which are used to help prevent severe cases of COVID-19.

The underlying core business looks solid, with operational sales growth of 8% (excluding Lagevrio), led by cancer drug Keytruda (up 17%). Merck’s steady pipeline innovation, especially the ...

Merck & Co has said it will ask the EMA’s human medicines committee (CHMP) to look again at a decision not to recommend approval of its antiviral Lagevrio for treating some people with COVID-19.